Abstract:

Malaria infection is one of the most significant public health problems and the leading cause of global morbidity and mortality. Pregnant women and under-five (U5) children are particularly at risk in areas where malaria is endemic. The U5 children account for about 80% of all malaria-related deaths. This study aims to assess the adherence to the national guidelines for administering seasonal malaria chemoprevention (SMC) in U5 children by healthcare workers (HCWs) working in public Primary Health Care (PHC) facilities in Edo State, Nigeria. A cross-sectional study design was employed to assess the sociodemographic characteristics, awareness, and prescription of chemo-preventive therapy for the U5 by 200 HCWs in public PHC facilities in Edo State, with the aid of the researcher-designed pretested, self-administered, semi-structured questionnaire. Descriptive and inferential data analyses were carried out using the IBM SPSS version 20 software. All p-values had two tails and were deemed statistically significant if < 0.05. The majority of HCWs (71.5%) did not adhere to the national guideline for using chemo-preventive treatment for malaria in children, and there was a statistically significant relationship between many sociodemographic factors and compliance. The length of the HCW’s work (in years) was a critical indicator of compliance with the recommendation. In conclusion, the use of malaria chemo-preventive treatment in accordance with the Nigerian malaria diagnosis and treatment guidelines is being practiced ineffectively by HCWs in public PHCs in Edo State. A longer period of employment (in years) predicts a better practice.

References:

[1] CDC, “Malaria’s Impact Worldwide,” Washington D. C., Feb. 2021.

[2] World Health Organization, “Malaria,” Malaria. WHO, Geneva, pp. 1–4, 2022. Accessed: Mar. 14, 2022. [Online]. Available: https://www.who.int/data/gho/data/themes/malaria.

[3] Centers for Disease Control and Prevention, “About Malaria,” U.S. Department of Health & Human Services, Dec. 12, 2021.

[4] P. Jagannathan and A. Kakuru, “Malaria in 2022: Increasing challenges, cautious optimism,” Nature Communications, vol. 13, no. 1. Nature Research, Dec. 01, 2022. Doi: 10.1038/s41467-022-30133-w.

[5] G. Gachelin, P. Garner, E. Ferroni, J. P. Verhave, and A. Opinel, “Evidence and strategies for malaria prevention and control: a historical analysis,” Malar J, vol. 17, no. 1, p. 96, Dec. 2018, Doi: 10.1186/s12936-018-2244-2.

[6] WHO, “Promoting malaria chemoprevention,” Geneva, Jun. 2022. Accessed: Sep. 03, 2023. [Online]. Available: https://www.who.int/activities/promoting-malaria-chemoprevention#.

[7] A. B. Tiono, A. Ouédraogo, C. Remy, and K. Hamed, “Treatment of Asymptomatic Carriers of Plasmodium falciparum with Artemether–Lumefantrine: Impact on the Prevalence of Anemia,” Infect Dis Ther, vol. 2, no. 1, pp. 47–58, Jun. 2013, Doi: 10.1007/s40121-013-0005-7.

[8] Federal Ministry of Health Nigeria, “National Guidelines for Diagnosis and Treatment of Malaria.,” Abuja, May 2020. Accessed: Feb. 15, 2022. [Online]. Available: https://mcp.gov.ng.

[9] C. Paul, R. Kramer, A. Lesser, C. Mutero, M. L. Miranda, and K. Dickinson, “Identifying barriers in the malaria control policymaking process in East Africa: insights from stakeholders and a structured literature review,” BMC Public Health, vol. 15, no. 1, p. 862, Dec. 2015, Doi: 10.1186/s12889-015-2183-6.

[10] D. M. Maslove, A. Mnyusiwalla, E. J. Mills, J. McGowan, A. Attaran, and K. Wilson, “Barriers to the effective treatment and prevention of malaria in Africa: A systematic review of qualitative studies,” BMC Int Health Hum Rights, vol. 9, no. 1, p. 26, Dec. 2009, Doi: 10.1186/1472-698X-9-26.

[11] Edo State Ministry of Health, “Edo State Government: State strategic health development plan (2010-2015),” Benin City, Nigeria., 2010.

[12] Edo State Ministry of Health, “2011 survey of health facilities in Edo State (Unpublished).,” Benin, 2011.

[13] Edo State Government, “Edo State Primary Healthcare Development Agency (EDPHCDA-PHCUOR) Implementation Committee Final Report,” Benin City, Nov. 2021.

[14] Edo State Government of Nigeria, “Primary Healthcare Under One Roof (PHCUOR) Implementation Committee’s Final Report,” Benin City, Nov. 2021.

[15] G. Cochran, Sampling Techniques, 2nd ed. New York: John Wiley and Sons, Inc., 1963.

[16] A. Mpimbaza et al., “Adherence to malaria management guidelines by health care workers in the Busoga sub-region, eastern Uganda,” Malar J, vol. 21, no. 1, p. 25, Jan. 2022, Doi: 10.1186/s12936-022-04048-2.

[17] R. Saadeh et al., “Osteoporosis among Postmenopausal Women in Jordan: A National Cross-Sectional Study,” Int J Environ Res Public Health, vol. 19, no. 14, p. 8803, Jul. 2022, Doi: 10.3390/ijerph19148803.

[18] IBM SPSS., “Statistical Package for the Social Sciences (SPSS) version 20.0. IBM SPSS;” 2014.

[19] C. V. Plowe, “Malaria chemoprevention and drug resistance: a review of the literature and policy implications,” Malar J, vol. 21, no. 1, p. 104, Mar. 2022, Doi: 10.1186/s12936-022-04115-8.

[20] S. Chatio, N. A. Ansah, D. A. Awuni, A. Oduro, and P. O. Ansah, “Community acceptability of
Seasonal Malaria Chemoprevention of morbidity and mortality in young children: A qualitative study in the Upper West Region of Ghana,” Plos One, vol. 14, no. 5, p. e0216486, May 2019, Doi: 10.1371/journal.pone.0216486.

[21] WHO, “Updated WHO recommendations for malaria chemoprevention among children and pregnant women,” Geneva, Jun. 2022. Accessed: Aug. 20, 2023. [Online]. Available: https://www.who.int/news/item/03-06-2022-Updated-WHO-recommendations-for-malaria-chemoprevention-among-children-and-pregnant-women.

[22] H. J. Oladipo et al., “Increasing challenges of malaria control in sub-Saharan Africa: Priorities for public health research and policymakers,” Annals of Medicine & Surgery, vol. 81, Sep. 2022, Doi: 10.1016/j.amsu.2022.104366.